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Al-Mallah et al. [1] present in the current is-
sue of Cardiology Journal a new meta-analysis
studying the impact of angiotensin-converting en-
zyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) on the incidence of new onset dia-
betes mellitus (DM). In 18 carefully selected ran-
domized controlled trials, they report this endpoint
with ACEI or ARB therapy vs comparators in more
than 100,000 patients. ACEI/ARB use was associa-
ted with a decrease in new onset DM of around 22%
for ACEI and 20% for ARB. So, one of the conclu-
sions to be drawn from this meta-analysis is that
this effect does not differ between ACEIs and ARBs.
This fully accords with the results of the prospec-
tive, landscape trial of head-to-head ramipril vs
telmisartan (the ONTARGET trial), in which the
new incidences of DM were very similar in both
groups [2].
In 1999, Yusuf et al. [3] reported a decrease in
new cases of DM in the HOPE trial in those taking
ramipril 10 mg daily vs placebo, although this was
a post hoc analysis. In the DREAM trial, ramipril 15 mg
daily did not prevent new cases of DM. However,
such a primary endpoint was reached in the sub-
group of those < 50 years old, and ramipril was sta-
tistically significantly better than placebo as far
as regression from glucose intolerance was stud-
ied. It also tended to be better in those with lower
body mass index, lower waist-to-hip ratio and those
whose systolic blood pressure was below 140 mm Hg
[4]. Thus, it could be concluded that ramipril 15 mg
daily may prevent DM in the very early stages of
metabolic syndrome.
The meta-analysis of Al-Mallah et al. [1] was
carried out in 2009, without knowing about the
NAVIGATOR trial results. It is interesting to look
at the carefully selected trials in their meta-analy-
sis. From those trials with ACEIs (captopril, enala-
pril, lisinopril, quinapril, ramipril and trandolapril)
only quinapril did not reach statistical significance
in DM prevention in its only trial reporting this
endpoint. Thus, the DM prevention by ACEIs might
be interpreted as the class effect of all those drugs.
However, if the regulatory agency was to one day
consider the potential indications for any ACEI in
DM prevention, only five ACEIs could be discussed:
captopril, enalapril, lisinopril, trandolapil and rami-
pril. These are, by the way, the ACEIs with the stron-
gest evidence for the reduction of the most impor-
tant endpoint in clinical trails — total mortality.
When we look at the trials selected for ARBs
(candesartan, losartan, telmisartan and valsartan),
only candesartan, losartan and valsartan might be
considered for DM prevention by regulatory agen-
cies, although from the pharmacological point of
view, telmisartan seems very interesting in terms
of DM prevention. It is the ARB which has the
most potent peroxisome proliferators-activated re-
ceptor-gamma (PPAR-g) activity, with potential
additional insulin-sensitizing/antidiabetic effect
[5]. It is very hard to explain why these pharma-
cological properties of telmisartan do not differen-
tiate this drug from its relatives in the ARB fami-
ly as far as the results of the clinical trials pub-
lished  to date are concerned.
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If we consider solely the positive trials for DM
prevention, and narrow our focus onto only those
where DM prevention was the pre-specified end-
point, only candesartan (ALPINE, CASE) and val-
sartan (VALUE, NAVIGATOR — not included in
this meta-analysis) meet the potential new indica-
tion according to European (EMEA) or American
(FDA) regulatory agencies, in my opinion. Of those
two drugs, valsartan is probably closer to such an
indication, due to the recently published NAVIGA-
TOR trial where this endpoint was a pre-specified
and primary one [6].
The Nateglinide And Valsartan in Impaired
Glucose Tolerance Outcomes Research study
(NAVIGATOR), presented in March 2010 at a meet-
ing of the American College of Cardiology, was
a multinational, double blind and randomized trial
that enrolled patients between January 2002 and
January 2004. One of the three primary endpoints
of NAVIGATOR was to look for reductions in the
incidence of new onset type 2 diabetes combined
with a reduction in postprandial hyperglycemia,
a blockade of the renin–angiotensin system, or both.
Contrary to the failure of nateglinide, valsartan vs
placebo significantly reduced the incidence of DM
by 14% during follow-up. The results of this trial
support the meta-analysis presented in the current
issue of Cardiology Journal, and if these results were
to be incorporated in the meta-analysis, it probably
would not the change the outcome. So we can con-
clude that ACEIs and ARBs decrease the probabi-
lity of new cases of DM by up to 20%.
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